CRC Research Update — September 20, 2026
Today's colorectal cancer research highlights
ctdna
A collection of 97 issues
ctDNA in the Management of Resectable & Advanced Colorectal Cancer
Skip to content
The CRC Digest
◇ RESEARCH
ctDNA in the Management of Resectable & Advanced Colorectal Cancer
A structured narrative review synthesizes evidence on circulating tumor DNA as a biomarker for molecular residual disease after curative-intent treatment, covering tumor-informed and tumor-agnostic assay strategies, postoperative sampling, and serial versus landmark testing
CRC Research Update — September 16, 2026
Today's colorectal cancer research highlights
Meta-analysis shows ctDNA after surgery strongly predicts recurrence risk
Skip to content
The CRC Digest
◇ RESEARCH
Meta-analysis shows ctDNA after surgery strongly predicts recurrence risk
A meta-analysis of seven prospective cohorts found that postoperative circulating tumor DNA positivity was associated with increased recurrence risk (pooled hazard ratio, 7.60; 95% CI, 4.70-12.31) after curative-intent colorectal cancer resection,
CRC Research Update — September 15, 2026
Today's colorectal cancer research highlights
CRC Research Update — September 11, 2026
Today's colorectal cancer research highlights
ctDNA-guided rechallenge with cetuximab plus irinotecan shows activity in RAS/BRAF wild-type mCRC
Skip to content
The CRC Digest
▸ TREATMENT
ctDNA-guided rechallenge with cetuximab plus irinotecan shows activity in RAS/BRAF wild-type mCRC
A Phase II trial enrolled patients with RAS/BRAF wild-type metastatic colorectal cancer who had progressed on prior cetuximab-based therapy, using circulating tumor DNA testing to select patients for rechallenge
Blood test combining cfDNA fragmentomics and methylation markers detects precancerous lesions
Skip to content
The CRC Digest
▪ SCREENING
Blood test combining cfDNA fragmentomics and methylation markers detects precancerous lesions
A study of 380 CRC patients, 121 individuals with precancerous lesions, and 506 healthy controls found that adding methylation analysis of SEPT9 and HS3ST2 to cfDNA fragmentomics improved detection of precancerous lesions,
CRC Research Update — September 07, 2026
Today's colorectal cancer research highlights
Meta-analysis finds conflicting evidence on ctDNA RAS testing for anti-EGFR therapy
Skip to content
The CRC Digest
◇ RESEARCH
Meta-analysis finds conflicting evidence on ctDNA RAS testing for anti-EGFR therapy
A systematic review of patients with tissue RAS wild-type tumors receiving first-line chemotherapy plus anti-EGFR therapy found inconsistent results on whether ctDNA RAS status predicts outcomes, possibly due to differences in assay